Drug pricing system

Recommendations

• It is necessary to examine the impact of evaluation on the rapid introduction of innovative drugs in Japan and the development of pediatric drugs, which were enhanced through the drug pricing system reform 2024.
• The rules for calculating the price of new drugs should be designed to ensure that innovation is properly evaluated and to avoid significantly lower drug prices in Japan compared to those in Europe and the US.
• For post-launch, it is necessary to examine the way in which the drug price revision system should be, taking the latest situation of drug distribution into account.
• The current rules for calculating NHI drug prices have become a very complicated system due to repeated reviews, and should be revised to a simpler, easier-to-understand and more transparent system.